Cell and gene therapy insurance, built for the highest limits and the longest tail.

The clinical-stage biotech stack - clinical trial liability, directors and officers, general liability and property, workers compensation, and cyber - but at higher limits and with two features a typical biotech does not manage as hard: a very long claims tail (FDA expects up to 15 years of long-term follow-up for gene therapy, so subject-injury claims can surface more than a decade after dosing), and distinctive manufacturing exposures (viral-vector production, autologous batches that cannot be remade, cryogenic cold chain, chain of identity). Once commercial, products liability is high-severity because the intervention is often irreversible.

Gene therapy sits at the top of the clinical trial liability range because the intervention is usually irreversible, the mechanism is novel, and the populations are often rare-disease or pediatric. First-in-human and pivotal gene-therapy trials commonly require $10M-$25M or more, frequently with a per-subject (per-claimant) sub-limit that ethics committees review closely. The controlling number is what the CTA, the IRB, and any applicable national law require for the specific study.

FDA calls for long-term follow-up of gene-therapy subjects for as long as 15 years to detect delayed events such as insertional oncogenesis. Because clinical trial liability and products coverage are usually claims-made, a company that lets coverage lapse at trial close-out leaves a decade-plus window of delayed-injury exposure uninsured. The fix is continuous claims-made coverage with the retroactive date preserved across renewals and carriers, plus a long extended reporting period (tail) purchased at close-out - budgeted from the start, since gene-therapy tail is expensive.

Viral-vector production and cell processing are contamination-sensitive and hard to re-validate after a loss. Autologous therapies are patient-specific, so a lost or compromised batch cannot simply be remade and a patient may go untreated - making a manufacturing loss simultaneously a property, business-interruption, and liability event. Cryogenic storage and cold-chain transport add property and cargo risk, and chain-of-identity requirements create process-failure exposure. The program needs property with validation and reprocessing, cargo and cold-chain coverage, and products and professional liability tuned to the process.

High-severity and long-tailed rather than high-frequency: the treated populations are small, but each potential injury is severe and often irreversible, and delayed events can surface years later. That drives substantial per-occurrence limits, a form chosen with the long tail in mind, and careful coordination with the clinical trial liability that preceded commercialization so there is no gap at the transition from trial to market. It is placed through specialty life-sciences markets, not a generic products carrier.

Because the science, the cGMP expectations, and the long-tail structure are specialized, cell and gene therapy programs are placed through the specialty life-sciences markets that understand the regulatory path and the manufacturing. Generalist carriers frequently exclude or mis-rate the exposure, particularly the long tail and the autologous manufacturing risk. A specialty broker accesses the right carrier panel and structures the retroactive-date continuity and tail from the outset.